Company Analysis

Cogent Biosciences, Inc. (COGT)

Nasdaq: COGT · Pharmaceutical Preparations · Waltham, MA · filing with the SEC since 2014
Grade4.3
◀ Past 4.3● Present 5.4▶ Future 3.2
2 est.

Who runs Cogent Biosciences, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Robbins Andrew R
President and CEO. First filing Oct 2020, latest May 21, 2026, 0 filings in all.
Officers reporting now
6
of 13 people with a filing in the last fifteen months
Directors reporting now
7
23 people on the record since 2018
Officerssales are open-market, Oct 5, 2025 to Oct 5, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Robbins Andrew RPresident and CEOOct 2020May 21, 2026none
Green John L.Chief Financial OfficerFeb 2019Dec 30, 20251 · $3.0M
Kearns EvanChief Legal OfficerMay 2021Dec 30, 20251 · $2.5M
Robinson John EdwardChief Scientific OfficerApr 2021Dec 30, 20251 · $3.5M
Sachs JessicaChief Medical OfficerJul 2019Dec 30, 20251 · $3.2M
Pinnow ColeChief Commercial OfficerMay 2024Dec 19, 2025none
Directorssales are open-market, Oct 5, 2025 to Oct 5, 2026
NameRoleFirst filingLatest filingSales, 12 months
Ferrante Karen JeandirectorMar 2018Oct 5, 2026none
Morris ArlenedirectorJul 2019Aug 31, 20262 · $1.7M
Cain Christopher W.directorJul 2020Jun 11, 2026none
Harwin Peter EvandirectorJul 2020Jun 11, 2026none
Ros MatthewdirectorJul 2019Jun 11, 2026none
Shegog TodddirectorFeb 2021Jun 11, 2026none
Fairmount Funds Management LLCdirectorJul 2020Mar 31, 20262 · $370M
Earlier names on the record24, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton COGT · research, not advice